GW 493838

Drug Profile

GW 493838

Alternative Names: 493838

Latest Information Update: 06 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Analgesics
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lipid metabolism disorders; Neuropathic pain

Most Recent Events

  • 06 Dec 2005 Discontinued - Phase-II for Lipid metabolism disorders in USA (unspecified route)
  • 30 Nov 2004 Discontinued - Phase-II for Neuropathic pain in United Kingdom (unspecified route)
  • 10 Dec 2003 Phase-II clinical trials in Lipid metabolism disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top